Jump to main content
Jump to site search

Issue 22, 2017
Previous Article Next Article

The discovery of half-sandwich iridium complexes containing lidocaine and (pyren-1-yl)ethynyl derivatives of phenylcyanamide ligands for photodynamic therapy

Author affiliations

Abstract

The successful design, synthesis, characterization, photophysical properties and anticancer mechanistic studies of a series of half-sandwich cyclopentadienyl iridium(III) complexes of the type [Cp*IrIII(LC)(L1)](PF6), 1, and [Cp*IrIII(LC)(L2)](PF6), 2, in which Cp* = pentamethylcyclopentadienyl, L1 = 4-(pyren-10-yl)ethynyl-phenylcyanamide, L2 = 4′-(pyren-10-yl)ethynyl-4-cyanamidobiphenyl, and LC = lidocaine, are reported for their application as photodynamic therapy (PDT) agents. The DNA binding, DNA photocleavage, cellular uptake, and apoptosis of the complexes have also been studied.

Graphical abstract: The discovery of half-sandwich iridium complexes containing lidocaine and (pyren-1-yl)ethynyl derivatives of phenylcyanamide ligands for photodynamic therapy

Back to tab navigation

Supplementary files

Publication details

The article was received on 27 Mar 2017, accepted on 06 May 2017 and first published on 08 May 2017


Article type: Paper
DOI: 10.1039/C7DT01091E
Citation: Dalton Trans., 2017,46, 7242-7252
  •   Request permissions

    The discovery of half-sandwich iridium complexes containing lidocaine and (pyren-1-yl)ethynyl derivatives of phenylcyanamide ligands for photodynamic therapy

    L. Tabrizi, Dalton Trans., 2017, 46, 7242
    DOI: 10.1039/C7DT01091E

Search articles by author

Spotlight

Advertisements